EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications

Hugo Boutier iD, Anja Feldmann, Michael Bachmann

International Journal of Molecular Sciences · 19.08.2026 · 27 (16) · 7425

DOI: 10.3390/ijms27167425 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.08.2026. Verfasst von Hugo Boutier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany. Hauptthemen laut MEDLINE: Neoplasms, Gelatinases, Serine Endopeptidases, Membrane Proteins. Die Arbeit nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marie Skłodowska-Curie Action OncoProTools, Helmholtz Initiative and Networking Fund (Radio-Immunotheranostics MHELTHERA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of hematologic malignancies but has demonstrated limited efficacy in solid tumors, mainly due to the complex and immunosuppressive tumor microenvironment (TME). Among the strategies to overcome this challenge, targeting the tumor stroma rather than the tumor cells themselves has gained increasing interest. In this context, fibroblast activation protein alpha (FAP), a cell surface protease overexpressed by cancer-associated fibroblasts, represents a promising target. With the aim of remodeling the TME, enhancing immune infiltration, and suppressing tumor growth, numerous FAP-directed CAR T-cell therapies have been developed in the last decade, leading to the clinical translation of two candidates. To improve the flexibility and safety profile of CAR T-cell therapies, several groups have designed more controllable and modular approaches, including adapter CAR T-cell systems, which enable on-demand activation of effector cells through the administration of an adapter molecule. In parallel, the development of FAP-targeted radiotracers, particularly FAP inhibitors (FAPIs), has enabled high-contrast imaging of solid tumors and introduced attractive opportunities for radioligand therapy. The convergence of these advances has given rise to immunotheranostic strategies that integrate CAR T-cell immunotherapy and radioligand delivery within a unified framework. This review traces the evolution of FAP-directed CAR T-cell strategies, from conventional designs to adapter-based and theranostic platforms, and examines how modular adapters bring immunotherapy and radioligand delivery together within a single immunotheranostic framework, across preclinical and clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsGelatinasesSerine EndopeptidasesMembrane ProteinsImmunotherapy, AdoptiveReceptors, Chimeric AntigenImmunotherapyHumansFibroblast Activation Protein AlphaEndopeptidasesAnimalsTumor MicroenvironmentT-Lymphocytes

Stichwörter der Autor:innen

CAR T-cellFAPIadapter CAR platformfibroblast activation protein (FAP)immunotheranosticstargeted radioligand deliverytheranosticstumor microenvironment

Substanzen

Fibroblast Activation Protein AlphaEndopeptidasesGelatinasesSerine EndopeptidasesMembrane ProteinsReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany.
  • National Center for Tumor Diseases (NCT), NCT/UCC Dresden, 01307 Dresden, Germany.
  • German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.

ORCID-Profile: Hugo Boutier

Förderung

  • Marie Skłodowska-Curie Action OncoProTools
  • Helmholtz Initiative and Networking Fund (Radio-Immunotheranostics MHELTHERA)

Zitieren

APA

Boutier, H., Feldmann, A., & Bachmann, M. (2026). The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications. International Journal of Molecular Sciences, 27(16), 7425. https://doi.org/10.3390/ijms27167425

Vancouver

Boutier H, Feldmann A, Bachmann M. The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications. International Journal of Molecular Sciences. 2026;27(16):7425. doi:10.3390/ijms27167425

BibTeX
@article{Boutier2026,
  author = {Boutier, Hugo and Feldmann, Anja and Bachmann, Michael},
  title = {The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7425},
  doi = {10.3390/ijms27167425}
}
Kostenlos starten →